Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Myriad Genetics (MYGN) EBT (2016 - 2025)

Historic EBT for Myriad Genetics (MYGN) over the last 17 years, with Q3 2025 value amounting to -$26.2 million.

  • Myriad Genetics' EBT fell 2358.49% to -$26.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$425.3 million, marking a year-over-year decrease of 26475.13%. This contributed to the annual value of -$123.5 million for FY2024, which is 5289.86% up from last year.
  • Latest data reveals that Myriad Genetics reported EBT of -$26.2 million as of Q3 2025, which was down 2358.49% from -$330.6 million recorded in Q2 2025.
  • In the past 5 years, Myriad Genetics' EBT ranged from a high of $39.8 million in Q3 2021 and a low of -$330.6 million during Q2 2025
  • Over the past 5 years, Myriad Genetics' median EBT value was -$37.2 million (recorded in 2024), while the average stood at -$51.0 million.
  • Its EBT has fluctuated over the past 5 years, first soared by 19107.55% in 2021, then tumbled by 78870.97% in 2025.
  • Myriad Genetics' EBT (Quarter) stood at -$43.5 million in 2021, then decreased by 19.77% to -$52.1 million in 2022, then surged by 38.0% to -$32.3 million in 2023, then decreased by 21.05% to -$39.1 million in 2024, then skyrocketed by 32.99% to -$26.2 million in 2025.
  • Its EBT was -$26.2 million in Q3 2025, compared to -$330.6 million in Q2 2025 and -$29.4 million in Q1 2025.